These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30939273)

  • 1. ECG Diagnosis: Ibutilide-induced Torsade de Pointes.
    Le DD; Levis JT; Lugovskaya N; Vinson DR
    Perm J; 2019; 23():. PubMed ID: 30939273
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ
    Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female preponderance in ibutilide-induced torsade de pointes.
    Gowda RM; Khan IA; Punukollu G; Vasavada BC; Sacchi TJ; Wilbur SL
    Int J Cardiol; 2004 Jun; 95(2-3):219-22. PubMed ID: 15193823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibutilide (Corvert): suspected association with torsades de pointes.
    CMAJ; 2004 Oct; 171(8):994. PubMed ID: 15497210
    [No Abstract]   [Full Text] [Related]  

  • 5. [Practical ECG problems. Torsade de pointes in an elderly patient].
    Isaza C; Trombert V
    Rev Med Suisse; 2012 May; 8(340):1025. PubMed ID: 22662633
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
    Glatter K; Yang Y; Chatterjee K; Modin G; Cheng J; Kayser S; Scheinman MM
    Circulation; 2001 Jan; 103(2):253-7. PubMed ID: 11208685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe ibutilide-induced arrhythmia in patients with heart failure].
    Harg P; Madsen S; Amlie JP
    Tidsskr Nor Laegeforen; 2001 Oct; 121(24):2834-5. PubMed ID: 11706492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A; Goldbarg S
    Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting torsade de pointes.
    Spodick DH
    Circulation; 1993 Jun; 87(6):2066-7. PubMed ID: 8504526
    [No Abstract]   [Full Text] [Related]  

  • 14. What is drug-induced long QT and what is a potential clinical consequence?
    Tsiperfal A; Gould M; Thompson C
    Prog Cardiovasc Nurs; 2006; 21(2):104-5. PubMed ID: 16760695
    [No Abstract]   [Full Text] [Related]  

  • 15. Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients.
    Coleman CI; Kalus JS; Caron MF; Kluger J; White CM
    Am J Health Syst Pharm; 2004 Apr; 61(7):685-8. PubMed ID: 15119574
    [No Abstract]   [Full Text] [Related]  

  • 16. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug.
    Wiesfeld AC; Crijns HJ; Bergstrand RH; Almgren O; Hillege HL; Lie KI
    Am Heart J; 1993 Oct; 126(4):1008-11. PubMed ID: 8213422
    [No Abstract]   [Full Text] [Related]  

  • 17. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
    Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
    Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of torsades de pointes caused by sotalol therapy.
    Cammu G; Geelen P; Baetens P; De Vos J; Demeyer I
    Resuscitation; 1999 Jan; 40(1):49-51. PubMed ID: 10321848
    [No Abstract]   [Full Text] [Related]  

  • 19. Propafenone-induced torsade de pointes: cross-reactivity with quinidine.
    Hii JT; Wyse DG; Gillis AM; Cohen JM; Mitchell LB
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 1):1568-70. PubMed ID: 1721143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis.
    Link MS; Foote CB; Sloan SB; Homoud MK; Wang PJ; Estes NA
    Chest; 1997 Aug; 112(2):556-7. PubMed ID: 9266902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.